Operating Grant : EUP OHAMR Joint Transnational Call 2026 (European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) JTC1 “OH-TREAT” Treatments and Adherence to Treatment Protocols)

Antimicrobials play a critical role in human health, animal health, agriculture, and food production, and drug-resistant microorganisms can spread between species and environments, exacerbating antimicrobial resistance (AMR). To address the interconnectedness of AMR and antimicrobial use (AMU) across sectors, a One Health approach that considers the interconnectedness of human, animal, plant, and environmental health is embedded within the ten priority actions and desired outcomes described in the Pan-Canadian Action Plan on AMR (PCAP).

CIHR is a member of the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR), a key partnership that has been identified by the European Commission within the framework of the Horizon Europe programme to support research and innovation to respond to the challenges of AMR.

This first translational call for the EUP OHAMR will support research to advance innovative, cost-effective AMR treatment options. Consistent with the One Health approach embedded within the PCAP and prioritized within CIHR-III's Strategic Plan for 2021-2026, projects must be relevant to the following topic area to receive CIHR funding:

Topic 3: Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use.

Proposals addressing this topic are expected to assess the impact of mechanisms of action, formulations, routes of administration and treatment regimens of antibacterial and antifungal drugs authorized for veterinary and agricultural use on the risk of emergence and transmission of AMR to humans and the environment. Proposals addressing this topic should also aim to improve the formulation, dosage, delivery, routes of administration and treatment regimens (including pharmacokinetics and pharmacodynamics) currently used in the veterinary and agricultural sector, to decrease the risk of cross-resistance, or transmission to humans and the environment. The aim is to generate evidence to support policies that restrict certain antimicrobials for exclusive human use.

Projects that do not address Topic 3 will not be deemed relevant and will not receive CIHR funding.